Physician profile
John G Stoner
NPI 1700859345
$971.17
in general payments reported to CMS, 2019-2025
16 companies · $26.41 in 2025
The $26.41 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $244 · 2024: $77.27 · 2025: $26.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.97 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $158.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $93.85 | 2019-2024 | |
| Celgene Corporation | $91.53 | 2019 | |
| Genentech USA, INC. | $87.21 | 2019-2020 | |
| Amgen INC. | $72.57 | 2019-2020 | |
| Leo Pharma INC. | $61.07 | 2019-2020 | |
| Dermira, INC. | $46.79 | 2019-2020 | |
| Lilly USA, LLC | $37.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $36.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.41 | 2025 | Spevigo |
| Aclaris Therapeutics, INC. | $25.56 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $22.63 | 2020 | |
| Almirall LLC | $16.00 | 2019 | |
| Janssen Biotech, INC. | $11.29 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $10.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.